Lymph node metastases displaying lower Ki-67 immunostaining activity than the primary breast cancer

Daniela Cabibi, Rosario Sanguedolce, Anna Martorana, Anna Calascibetta, Claudio Tripodo, Aragona, Campione, Mustacchio, Anna Martorana, Tripodo, Calascibetta, Rosario Sanguedolce, Cabibi

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


The aim of the study was to verify by Ki-67 immunostaining if any difference exists in the cell proliferating fraction between primary breast tumors (PTs) and matching positive axillary lymph nodes (ALNs).PATIENTS AND METHODS: Immunohistochemistry with the monoclonal antibody against Ki-67 was performed in 160 node-positive breast carcinomas and in their respective lymph node metastases.RESULTS: An increase of Ki-67 immunoreactive cells in ALN compared with that of PTs was observed in 84% of cases (ALN: mean 17%, PTs: mean 8%; p < 0.001), whereas 16% of the cases showed Ki-67 value two to six times lower in the ALNs than in the corresponding PTs (ALN: mean 3.2%, PTs mean 12.5%; p < 0.005). The decrease of Ki-67 positive cells in the ALN was independent from the histotype and the histological grade of the tumor.CONCLUSION: A different cell proliferation fraction between PTs and matching positive ALNs was demonstrated and underlined that the existence of a group of patients with decreased number of Ki-67 immunoreactive cells in lymph node metastases compared with that of the primary tumors could be taken into account in the choice of therapeutic strategy.
Original languageEnglish
Pages (from-to)4357-4360
Number of pages4
JournalAnticancer Research
Publication statusPublished - 2006

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Lymph node metastases displaying lower Ki-67 immunostaining activity than the primary breast cancer'. Together they form a unique fingerprint.

Cite this